Nkarta (NKTX) vs Organigram Global (OGI)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
Nkarta (NKTX) has outperformed Organigram Global (OGI) over the past year, losing 21.7% versus a loss of 49.1%. Over five years, NKTX leads with a -89.5% price change compared with -90.1% for OGI. Organigram Global is the larger company by market cap ($133.6 million vs $128.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | NKTX | OGI |
|---|---|---|
| Share price | $1.80 | $0.9267 |
| Market cap | $128.92M | $133.59M |
| 1-day change | -6.74% | -0.53% |
| YTD return | -2.70% | -44.84% |
| 1-year return | -21.74% | -49.08% |
| 5-year return | -89.49% | -90.10% |
| P/E ratio (TTM) | — | 2.16 |
| Forward P/E | — | 38.61 |
| EPS (TTM) | $-1.58 | $0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $0 | — |
| Net income (latest FY) | $-104.08M | — |
| 52-week high | $3.72 | $2.24 |
| 52-week low | $1.70 | $0.853 |
| Distance from 52-week high | -51.61% | -58.63% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +501.67% | — |
| Average volume | 641.25K | 855.47K |
| Shares outstanding | 71.62M | 144.15M |
| Employees | 106 | 1,139 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- NKTX has outperformed OGI by 27.3 percentage points over the past year.
About Nkarta
NKTX stock →Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis.
Health Care · Biotechnology: Pharmaceutical Preparations · 106 employees
About Organigram Global
OGI stock →Organigram Global Inc. engages in the production and sale of cannabis and cannabis-derived products in Canada.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,139 employees
NKTX vs OGI FAQ
Which is bigger, Nkarta or Organigram Global?
Organigram Global (OGI) is larger, with a market capitalization of $133.59M compared with $128.92M for Nkarta (NKTX).
Which stock has performed better over the past year, NKTX or OGI?
NKTX returned -21.74% over the past 12 months, compared with -49.08% for OGI (price return, excluding dividends). Past performance does not predict future results.
Are Nkarta and Organigram Global in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.